Restraining Serum Institute from using 'COVISHIELD' name will disrupt COVID-19 vaccination programme: Bombay High Court in Trademark case

The observation was made in a plea by Cutis Biotech seeking an order of injunction against Serum Institute from using the trademark COVISHIELD which Cutis claimed ought to belong to them.

The Bombay High Court on Tuesday refused to restrain Serum Institute of India (SII) from using the mark 'COVISHIELD' for its vaccine against the COVID-19 virus on the ground that SII was the prior user of the mark, had acquired enough goodwill and that discontinuing the name would create confusion and disruption in the vaccination programme (Cutis Biotech v. Serum Institute of India).

Loading content, please wait...
Bar and Bench - Indian Legal news